TPST Tempest Therapeutics, Inc. Stock Quote

TPST [NASD]

Index	-	P/E	-	EPS (ttm)	-11.14	Insider Own	1.10%	Shs Outstand	7.17M	Perf Week	-6.81%
Market Cap	21.64M	Forward P/E	-	EPS next Y	-4.16	Insider Trans	-	Shs Float	5.70M	Perf Month	-43.26%
Income	-31.40M	PEG	-	EPS next Q	-0.92	Inst Own	31.90%	Short Float	4.06%	Perf Quarter	-44.42%
Sales	-	P/S	-	EPS this Y	74.20%	Inst Trans	-7.40%	Short Ratio	0.70	Perf Half Y	-62.50%
Book/sh	4.10	P/B	0.53	EPS next Y	-7.60%	ROA	-44.50%	Target Price	22.50	Perf Year	-83.61%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-80.00%	52W Range	2.00 - 41.00	Perf YTD	-58.52%
Dividend	-	P/FCF	-	EPS past 5Y	58.10%	ROI	-	52W High	-94.66%	Beta	0.47
Dividend %	-	Quick Ratio	3.00	Sales past 5Y	-	Gross Margin	-	52W Low	9.50%	ATR	0.33
Employees	17	Current Ratio	3.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	38.86	Volatility	13.43% 12.29%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	81.80%	Profit Margin	-	Rel Volume	0.04	Prev Close	2.29
Shortable	Yes	LT Debt/Eq	0.51	Earnings	Mar 29 AMC	Payout	-	Avg Volume	330.21K	Price	2.19
Recom	1.70	SMA20	-14.10%	SMA50	-24.92%	SMA200	-66.23%	Volume	13,204	Change	-4.37%

Jun-09-22 08:00AM	Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance GlobeNewswire
Jun-06-22 04:05PM	Tempest to Present at the Jefferies Healthcare Conference GlobeNewswire -12.50%
May-26-22 04:57PM	Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting GlobeNewswire
May-13-22 08:00AM	Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights GlobeNewswire +5.88%
Apr-27-22 10:01AM	Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting GlobeNewswire +30.08%
08:00AM	Tempest Announces Private Placement Financing of $15 Million GlobeNewswire
Apr-08-22 01:00PM	Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting GlobeNewswire
Mar-29-22 04:00PM	Tempest Reports Year End 2021 Financial Results and Provides Business Update GlobeNewswire
Mar-10-22 08:00AM	Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference GlobeNewswire -9.23%
Mar-08-22 04:30PM	Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Feb-09-22 08:00AM	Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference GlobeNewswire
Nov-18-21 08:00AM	Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab GlobeNewswire
Nov-12-21 07:00AM	Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer GlobeNewswire
Nov-10-21 04:05PM	Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights GlobeNewswire
Nov-09-21 08:00AM	Tempest to Present at Two Upcoming Investor Conferences in November GlobeNewswire
Nov-08-21 08:00AM	Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495 GlobeNewswire
Oct-01-21 08:00AM	Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting GlobeNewswire
Sep-20-21 08:00AM	Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche GlobeNewswire
Sep-13-21 08:00AM	Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target GlobeNewswire
Sep-09-21 04:01PM	Tempest to Present at Upcoming Investor Conferences GlobeNewswire
Aug-12-21 04:01PM	Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights GlobeNewswire
Aug-09-21 08:00AM	Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors GlobeNewswire +8.09%
Jul-09-21 08:00AM	Tempest to Participate in William Blair 2021 Biotech Focus Conference GlobeNewswire +49.38%
Jul-01-21 04:00PM	Tempest Announces Appointment of Christine Pellizzari to its Board of Directors GlobeNewswire

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Woiwode Thomas	Director	Apr 29	Buy	2.36	2,118,644	5,000,000	2,118,644	May 03 05:49 PM
Dubensky Thomas W.	President	Jan 07	Buy	4.78	2,000	9,560	113,343	Jan 11 06:36 PM
Whiting Samuel	Chief Medical Officer	Jan 06	Buy	4.80	1,700	8,168	1,901	Jan 10 06:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience